Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL

Journal of Controlled Release

Volumn 228, Issue , 2016, Pages 96-106

  Li, Rui ^a   Yang, Hao ^a   Jia, Dianlong ^a   Nie, Qianxue ^a   Cai, Huawei ^a   Fan, Qing ^a   Wan, Lin ^a   Li, Lin ^a   Lu, Xiaofeng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Albumin; Albumin binding domain; Anti cancer drug; Cancer biotherapy; Drug delivery; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

BODY FLUIDS; CELL DEATH; DISEASES; DRUG DELIVERY; DRUG PRODUCTS; GLYCOPROTEINS; LIGANDS; MACROPHAGES; MAMMALS; TUMORS;

ALBUMIN; ALBUMIN BINDINGS; ANTICANCER DRUG; CANCER BIOTHERAPY; TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGANDS;

BINS;

ALBUMIN; ALBUMIN BINDING DOMAIN FUSION RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; DEATH RECEPTOR; HUMAN SERUM ALBUMIN; NANOPARTICLE; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; HYBRID PROTEIN; PROTEIN BINDING; SERUM ALBUMIN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS ASSAY; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL KILLING; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG UPTAKE; GLOMERULUS FILTRATION; HALF LIFE TIME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN DOMAIN; SINGLE DRUG DOSE; SURFACE PLASMON RESONANCE; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HALF-LIFE; HUMANS; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84960398645     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.03.004     Document Type: Article

References (42)

1. J.F.R. Kerr, C.M. Winterford, and B.V. Harmon Apoptosis. its significance in cancer and cancer therapy Cancer 73 1994 2013 2026
2. M.W. den Hollander, J.A. Gietema, S. de Jong, A.M. Walenkamp, A.K. Reyners, C.N. Oldenhuis, and E.G. de Vries Translating TRAIL-receptor targeting agents to the clinic Cancer Lett. 332 2013 194 201
3. B. Lim, J.E. Allen, V.V. Prabhu, M.K. Talekar, N.K. Finnberg, and W.S. El-Deiry Targeting TRAIL in the treatment of cancer: new developments Expert Opin. Ther. Targets 19 2015 1171 1185
4. E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J.J. Peschon, and M.J. Smyth Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice J. Immunol. 168 2002 1356 1361
5. L.M. Sedger, M.B. Glaccum, J.C.L. Schuh, S.T. Kanaly, E. Williamson, N. Kayagaki, T. Yun, P. Smolack, T. Le, R. Goodwin, and B. Gliniak Characterization of the in vivo function of TNF-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice Eur. J. Immunol. 32 2002 2246 2254
6. D.W. Stuckey, and K. Shah TRAIL on trial: preclinical advances in cancer therapy Trends Mol. Med. 19 2013 685 694
7. S.K. Kelley, L.A. Harris, D. Xie, L. Deforge, K. Totpal, J. Bussiere, and J.A. Fox Preclinical studies to predict the disposition of apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety J. Pharmcol. Exp. Ther. 299 2001 31 38
8. R.S. Herbst, S.G. Eckhardt, R. Kurzrock, S. Ebbinghaus, P.J. O'Dwyer, M.S. Gordon, W. Novotny, M.A. Goldwasser, T.M. Tohnya, B.L. Lum, A. Ashkenazi, A.M. Jubb, and D.S. Mendelson Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer J. Clin. Oncol. 28 2010 2839 2846
9. R. Trivedi, and D.P. Mishra Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells Front. Oncol. 5 2015 69
10. T.H. Kim, Y.S. Youn, H.H. Jiang, S. Lee, X. Chen, and K.C. Lee PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects Bioconjug. Chem. 22 2011 1631 1637
11. H. Wang, J.S. Davis, and X. Wu Immunoglobulin Fc domain fusion to TRAIL significantly prolongs its plasma half-life and enhances its antitumor activity Mol. Cancer Ther. 13 2014 643 650
12. S.M. Lim, T.H. Kim, H.H. Jiang, C.W. Park, S. Lee, X. Chen, and K.C. Lee Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles Biomaterials 32 2011 3538 3546
13. N. Muller, B. Schneider, K. Pfizenmaier, and H. Wajant Superior serum half life of albumin tagged TNF ligands Biochem. Biophys. Res. Commun. 396 2010 793 799
14. H.J. Byeon, S.Y. Min, I. Kim, E.S. Lee, K.T. Oh, B.S. Shin, K.C. Lee, and Y.S. Youn Human serum albumin-TRAIL conjugate for the treatment of rheumatoid arthritis Bioconjug. Chem. 25 2014 2212 2221
15. T.H. Kim, H.H. Jiang, Y.S. Youn, C.W. Park, S.M. Lim, C.H. Jin, K.K. Tak, H.S. Lee, and K.C. Lee Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution J. Pharm. Sci. 100 2011 482 491
16. D. Sleep, J. Cameron, and L.R. Evans Albumin as a versatile platform for drug half-life extension Biochim. Biophys. Acta 1830 2013 5526 5534
17. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 2008 171 183
18. F. Kratz, and B. Elsadek Clinical impact of serum proteins on drug delivery J. Control. Release 161 2012 429 445
19. Y. Shahzada, I.U. Khanb, T. Hussaind, A. Yuchi, C.A. Serra, S.A. Rizvif, M. Gerbera, and J. du Plessisa Bioactive albumin-based carriers for tumour chemotherapy Curr. Cancer Drug Targets 14 2014 752 763
20. D. Sleep Albumin and its application in drug delivery Expert Opin. Drug Deliv. 12 2015 793 812
21. R.E. Kontermann Strategy to extending half-life of recombinant antibody BioDrugs 23 2009 93 109
22. A. Jonsson, J. Dogan, N. Herne, L. Abrahmsen, and P.A. Nygren Engineering of a femtomolar affinity binding protein to human serum albumin Protein Eng. Des. Sel. 21 2008 515 527
23. F.Y. Frejd Half-life extension by binding to albumin through an albumin binding domain Roland Kontermann, Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives first ed. 2012 269 283
24. R. Stork, D. Muller, and R.E. Kontermann A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G Protein Eng. Des. Sel. 20 2007 569 576
25. A. Orlova, A. Jonsson, D. Rosik, H. Lundqvist, M. Lindborg, L. Abrahmsen, C. Ekblad, F.Y. Frejd, and V. Tolmachev Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein J. Nucl. Med. 54 2013 961 968
26. M. Malm, T. Bass, L. Gudmundsdotter, M. Lord, F.Y. Frejd, S. Stahl, and J. Lofblom Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension Biotechnol. J. 9 2014 1215 1222
27. H. Liu, J. Seijsing, F.Y. Frejd, V. Tolmachev, and T. Graslund Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain Int. J. Oncol. 47 2015 601 609
28. J. Lindgren, E. Refai, S.V. Zaitsev, L. Abrahmsen, P.O. Berggren, and A.E. Karlstrom A GLP-1 receptor agonist conjugated to an albumin-binding domain for extended half-life Biopolymers 102 2014 252 259
29. D. Jia, H. Yang, L. Wan, J. Cheng, and X. Lu Production of bioactive, SUMO-modified, and native-like TNF-alpha of the rhesus monkey, Macaca mulatta, in Escherichia coli Appl. Microbiol. Biotechnol. 93 2012 2345 2355
30. H. Yang, H. Cai, L. Wan, S. Liu, S. Li, J. Cheng, and X. Lu Bombesin analogue-mediated delivery preferentially enhances the cytotoxicity of a mitochondria-disrupting peptide in tumor cells PLoS One 8 2013 e57358
31. X. Ming, K. Carver, and L. Wu Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides Biomaterials 34 2013 7939 7949
32. Q. Chen, C. Liang, X. Wang, J. He, Y. Li, and Z. Liu An albumin-based theranostic nano-agent for dual-modal imaging guided photothermal therapy to inhibit lymphatic metastasis of cancer post surgery Biomaterials 35 2014 9355 9362
33. D. Wei, Q. Fan, H. Cai, H. Yang, L. Wan, L. Li, and X. Lu CF750-A33scFv-Fc-based optical imaging of subcutaneous and orthotopic xenografts of GPA33-positive colorectal cancer in mice BioMed Res. Int. 2015 2015 505183
34. F. Wang, L. Chen, R. Zhang, Z. Chen, and L. Zhu RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer J. Control. Release 196 2014 222 233
35. Q. Fan, H. Cai, H. Yang, L. Li, C. Yuan, X. Lu, and L. Wan Biological evaluation of 131I- and CF750-labeled Dmab(scFv)-Fc antibodies for xenograft imaging of CD25-positive tumors BioMed Res. Int. 2014 2014 459676
36. M.J. Mitchell, E. Wayne, K. Rana, C.B. Schaffer, and M.R. King TRAIL-coated leukocytes that kill cancer cells in the circulation Proc. Natl. Acad. Sci. U. S. A. 111 2014 930 935
37. C. Chaudhury, S. Mehnaz, J.M. Robinson, W.L. Hayton, D.K. Pearl, D.C. Roopenian, and C.L. Anderson The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan J. Exp. Med. 197 2003 315 322
38. A. Sethi, M. Sher, M.R. Akram, S. Karim, S. Khiljee, A. Sajjad, S.N. Shah, and G. Murtaza Albumin as a drug delivery and diagnostic tool and its market approved products Acta Pol. Pharm. 70 2013 597 600
39. J.T. Andersen, R. Pehrson, V. Tolmachev, M.B. Daba, L. Abrahmsen, and C. Ekblad Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain J. Biol. Chem. 286 2011 5234 5241
40. S.H. Kim, K. Kim, J.G. Kwagh, D.T. Dicker, M. Herlyn, A.K. Rustgi, Y. Chen, and W.S. El-Deiry Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells J. Biol. Chem. 279 2004 40044 40052
41. F. Zhang, M.R. Liu, and H.T. Wan Discussion about several potential drawbacks of PEGylated therapeutic proteins Biol. Pharm. Bull. 37 2014 335 339
42. M. Loi, P. Becherini, L. Emionite, A. Giacomini, I. Cossu, E. Destefanis, C. Brignole, D. Di Paolo, F. Piaggio, P. Perri, M. Cilli, F. Pastorino, and M. Ponzoni sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib J. Control. Release 192 2014 157 166